[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579850":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":39,"centralContacts":43,"locations":51,"responsibleParty":68,"collaborators":26,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":26,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":26,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":53,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8,14,17],{"label":9,"type":6,"description":9,"interventionNames":10},"Patients who request cryopreservation of ovarian tissue",[11,12,13],"Other: Step 1","Other: Step 2","Other: Step 3",{"label":15,"type":6,"description":15,"interventionNames":16},"Patients with already cryopreserved ovarian tissue at the criobank",[12,13],{"label":18,"type":6,"description":18,"interventionNames":19},"Patients who request ovarian tissue reimplantation",[12,13,20],"Other: Step 4",[22,27,31,35],{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"Step 1","Cryopreservation of ovarian tissue",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Step 2","Analysis of tumor markers in the primary tumor",[9,18,15],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Step 3","Search for neoplastic cells in cryopreserved ovarian tissue",[9,18,15],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":26},"Step 4","Cryopreserved ovarian tissue autotransplantation",[18],[40],{"name":41,"affiliation":5,"role":42},"Renato Seracchioli, MD","PRINCIPAL_INVESTIGATOR",[44,48],{"name":41,"role":45,"phone":46,"phoneExt":26,"email":47},"CONTACT","+390512143944","renato.seracchioli@aosp.bo.it",{"name":49,"role":45,"phone":26,"phoneExt":26,"email":50},"Rossella Vicenti","rossella.vicenti@unibo.it",[52],{"facility":5,"status":53,"city":54,"state":26,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Bologna","40138","Italy","IT",{"type":59,"coordinates":60},"Point",[61,62],11.33875,44.49381,{"lat":62,"lon":61},[65,66,67],{"name":41,"role":45,"phone":46,"phoneExt":26,"email":47},{"name":49,"role":45,"phone":26,"phoneExt":26,"email":50},{"name":41,"role":42,"phone":26,"phoneExt":26,"email":26},{"type":69,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100579850","cryopreserved-ovarian-tissue-transplantation-in-patients-who-have-survived-sarcomas-and-hematological-tumors-100579850",false,"NCT06829654","Cryopreserved Ovarian Tissue Transplantation in Patients Who Have Survived Sarcomas and Hematological Tumors","Safety Assessment Of Cryopreserved Ovarian Tissue Transplantation In Patients Who Have Survived Sarcomas And Hematological Tumors","Inclusion Criteria:\n\nFor all groups:\n\n* Patients with Ewing (ES) and synovial (SS) sarcoma, acute lymphoblastic leukemia (LLA), acute myeloid leukemia (LMA), chronic myeloid leukemia (LMC) and myelodysplasia (MDS)\n* No objection to the procedure of sampling for cryopreservation or reimplantation of ovarian tissue by the patient's reference oncologist (according to PA105)\n* Obtaining informed consent.\n\nGroup 1:\n\n* Age \\>18 and under 38 at the time of cryopreservation\n* Request for cryopreservation of ovarian tissue at the Laboratory Cryopreservation Ovarian Tissue and Cell Cultures\u002FCriobank IRCCS AOUBO\n\nGroup 2:\n\n* Age \\>18 years\n* Ovarian tissue already collected and cryopreserved at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures\u002FCriobank IRCCS AOUBO\n\nGroup 3\n\n* Age \\> 18 years\n* Request for reimplantation of cryopreserved ovarian tissue at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures\u002FCriobank IRCCS AOUBO\n* Early menopause or menstrual irregularities\n\nExclusion Criteria:\n\nGroup 1 and 3\n\n* Contraindications to laparoscopy\n* HIV, hepatitis B and C, treponema pallidum and positive PAP tests\n* Malignant disease involving the ovary or samples to be reimplanted\n\nGroup 2 None.","FEMALE","18 Years","38 Years",{"count":81,"type":82},80,"ESTIMATED","INTERVENTIONAL",[85],"NA","The study aims to test for the presence or absence of primary tumor-specific tumor markers in ovarian tissue. Therefore, there will be a first phase in which pathology-specific markers will be identified in the patients' diagnostic pathological material by histological, immunohistochemical, and molecular analysis; then, tumor markers will be sought in cryopreserved ovarian tissue.",[88,89],"Sarcomas","Haematological Malignancies",[91,92,93,94],"sarcomas","haematological malignancies","cryopreservation","ovarian tissue","2025-02-11",{"date":97,"type":98},"2025-02-17","ACTUAL",{"date":100,"type":98},"2024-08-12",{"date":102,"type":82},"2026-08-12",{"name":5,"class":6},1]